3SOF

time to pull the plug on GNBT? currently sitting at 1.28

think we'll get a run to close over the 1.29 sell mark?

Quote from: stopthemadness on November 08, 2005, 02:22:46 PM
time to pull the plug on GNBT? currently sitting at 1.28

think we'll get a run to close over the 1.29 sell mark?

Sorry stopthemadness (nice nick ), I wasn't looking when you wrote this post. I left the instructions and Ramsburg sold our GNBT shares at $1.26 before the close, according to the plan.

Unfortunately the stock could not continue running higher yesterday, so we had to sell it, since this is a Fast Portfolio.

I was unable to sell yesterday...maybe be a good thing.

Today's news:
Generex Biotechnology Proposes Collaborations in China for the Co-Development of a Novel Vaccine for Pandemic Avian Influenza
http://biz.yahoo.com/iw/051109/0100680.html

Peptide-Based Vaccine Offers Easy Scale-Up and Flexibility in Preparing for Possible Pandemic Bird Flu Threat


TORONTO--(MARKET WIRE)--Nov 9, 2005 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, has made proposals for co-development of the Antigen Express novel H5N1 avian influenza vaccine in China following a trip to Beijing by Dr. Minzhen Xu, the Antigen Express Vice-President of Biology.


Proposals were made to: Professor Hualan Chen of the Harbin Veterinary Research Institute; Ms. Nan Wang, Vice General Manager of Sinovac Biotech Co., Ltd.; and Professor Bing Sun of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. All have an interest in vaccine development for the H5N1 avian influenza in China.

The vaccine technology being employed at Antigen Express for the potentially pandemic avian influenza is the same as that for its novel immunotherapeutic cancer vaccine currently in clinical trials. "The basis of this technology lies in identifying portions of a specific disease-associated protein that are capable of stimulating T-helper cells which are subsequently modified to augment their vaccine potency," explained Dr. Xu. "T-helper cells play a critical role in generating an immune response to a novel foreign agent, directing other immune cells against that threat, and in establishing immunological 'memory' of that agent. Once these cells are stimulated, it is much easier to mount an effective response against an agent such as the H5N1 influenza virus."

Antigen Express has extant collaborations in China focusing on SARS and a novel immunotherapy strategy for patients with acute myeloid leukemia. "These relationships provide a convenient platform for expanding into avian influenza in China," said Dr. Eric von Hofe, President of Antigen Express. "The danger posed by avian influenza in China is more acute, given the recent outbreaks of the H5N1 strain in birds there, and they face the same supply limitations on traditional vaccines as are faced throughout the world. Furthermore, vaccinating people close to hot spots of H5N1 outbreaks is recognized as the best way to control a possible pandemic." Current estimates are that the world capacity per year for production of H5N1 vaccine by traditional methods would protect less than 40 million people.

Scientists at Antigen Express are developing a vaccine for the potentially pandemic Asian bird flu utilizing highly conserved fragments of the H5 protein to stimulate potent T-helper cell activity. The H5 fragments are modified using a portion of an immunoregulatory protein (termed Ii-Key) that greatly facilitates their ability to stimulate T-helper cell responses specific to the H5N1 strain. The vaccine peptides have been selected for their likelihood of being both potent and active in more than 90% of the population. This technology has the advantage of being applicable to any novel agent or protein once one has sequence information. As vaccine peptides are manufactured by entirely synthetic means they can be produced rapidly, relatively inexpensively, and in large quantities (hundreds of millions of doses).

Hi

Me too! My computer at work blocked some sites so I couldn't sell.

Now I will watch closely. Today's news is good.

Lalitha

Quote

Sorry stopthemadness (nice nick ), I wasn't looking when you wrote this post. I left the instructions and Ramsburg sold our GNBT shares at $1.26 before the close, according to the plan.

Quote

No problem David, like a few here, i never got around to selling. since it had a pretty good opening, i decided to hold and see what happens today.

Generex Biotechnology Submits Purchase Orders for Filling Equipment for Large-Scale Commercial Production of Oral-Lyn(TM)
Company to Launch First Approved Non-Injectable Insulin at Month-End
11/11/2005 9:02:06 AM

TORONTO, Nov 11, 2005 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT), a leader in the area of buccal drug delivery, today announced that it has submitted purchase orders for the acquisition of custom-made, semi-automatic filling equipment for the large-scale commercial production of Oral-lyn(TM), the Company's proprietary oral insulin spray product, which is delivered into the human mouth by way of the Company's proprietary RapidMist(TM) drug delivery system. The equipment will be used in the Company's launch of the product in Ecuador at the end of this month. Oral-lyn(TM) has been approved for commercial marketing and sale by the Ecuadorian Ministry of Public Health for the treatment of both Type-1 and Type-2 diabetes. The Company and PharmaBrand, S.A. (www.pharmabrand.com.ec), the Company's South American joint venture partner in Quito, Ecuador, are making preparations for the launch of commercial sales. Oral-lyn(TM) is the only non-injectable form of insulin approved for sale anywhere in the world.


This equipment, which constitutes a turnkey Oral-lyn(TM) filling operation, is a companion to the RapidMist(TM) value production equipment acquired by the Company in August, 2005. The equipment will be assembled and tested by the Company's third-party supplier in London, U.K. and shipped directly to the manufacturing facilities of PharmaBrand.

The equipment will allow for the filling of several canisters of Oral-lyn(TM) per minute and will be initially devoted to supporting Oral-lyn(TM) sales in Ecuador. The Company and PharmaBrand are also preparing to file materials for the approval of Oral-lyn(TM) by the other Andean Community countries and this equipment acquisition will allow Generex to service commercial sales in those markets as well.

Keep an eye on GNBT, this is what we been waiting on.

Generex Biotechnology Achieves Compliance With Nasdaq Capital Market Continued Listing Requirements
11/15/2005 9:05:04 AM


TORONTO, Nov 15, 2005 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT) announced today that on November 14, 2005 it received written confirmation from the Nasdaq Stock Market that the Company has achieved compliance with the continued listing requirements in accordance with Nasdaq Marketplace Rule 4310(c)(4).

Generex Biotechnology Retains Washington, D.C. - Based Lobbyist to Pursue Opportunities for Oral Insulin & Its Avian Flu Vaccine
11/17/2005 9:02:04 AM

TORONTO, Nov 17, 2005 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT) announced today that it has retained Washington, D.C. - based Sandler, Travis & Rosenberg, P.A. (www.strtrade.com) to provide assistance in connection with the Company's global clinical, regulatory, and commercialization program for Oral-lyn(TM), its proprietary oral insulin spray product, and in connection with the Antigen Express avian flu vaccine program. ST&R will assist the Company with White House and Congressional relations, relationships with administrative agencies, including the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention, and the U.S. Department of Health & Human Services, and relationships with foreign governments. ST&R will also assist in the Company's efforts to access governmental and private funding sources.

ST&R has been recognized as one of the preeminent international trade and government relations providers in the United States. ST&R brings together an aggressive team of Washington insiders and international strategists that includes legislative, regulatory, legal, economic, and industry experts.


Generex Biotechnology Retains Rubenstein Public Relations
11/17/2005 9:00:16 AM


TORONTO, Nov 17, 2005 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT) announced today that it has retained Rubenstein Public Relations (RPR) (www.rubensteinpr.com) as its public relations consultant. RPR will seek to publicize the Company and its product pipeline, including Oral-lyn(TM), the Company's proprietary oral insulin spray product, and the avian influenza vaccine program of Antigen Express, the Company's wholly owned immuotherapeutics subsidiary.
RPR is synonymous with integrated media campaigns, special events, and high visibility coverage. Thirty professionals demonstrate the power of publicity every day for the firm's corporate, consumer, and entertainment clients across the country. RPR, founded by Richard Rubenstein over 15 years ago, is one of New York City's premier media agencies.

Outsider prepares to launch diabetes blockbuster
Generex has escalated manufacturing capabilities to meet demand for the first commercially available non-injectable insulin product, to be launched in Ecuador this month.

http://www.in-pharmatechnologist.com/news/ng.asp?n=63967-generex-oral-lyn-insulin

DJ Generex, Pharmabrand To Produce Oral Insulin For Lat Am

11/28/2005
Dow Jones News Services
(Copyright © 2005 Dow Jones & Company, Inc.)



QUITO (Dow Jones)--Canada's Generex Biotechnology (GNBT) and Ecuador's Pharmabrand SA will next year start production of oral insulin for export within Latin America.

With an initial investment of $22 million to manufacture the drug in Ecuador, "Oral-lyn," as the spray will be called, took Generex about 10 years to develop.

"We will be the first in the world to make it and the first to market oral insulin - first in Ecuador, and then progressively throughout Latin America," Pharmabrand President Roberto Cid told reporters.

Generex head Anna Gluskin said the company chose Ecuador given its strategic location, facilitating distribution of the drug throughout the region.

The Oral-lyn will be made in a Pharmabrand pharmaceuticals plant located in Quito, which is one of the most modern facilities in Ecuador.

The companies also hope to receive permission to sell the products elsewhere in Latin America, starting in the second half of next year. That includes selling first in Colombia, Venezuela, Bolivia and Peru, where common Andean region regulations exist, and then later in Brazil, Mexico, Chile and Argentina.

The companies forecast sales in all of Latin America of some $300 million a year. 


-By Mercedes Alvaro, Dow Jones Newswires; 5939-9728-653; [email protected]

Up 5% in AH. Should have a nice gap up tomorrow. The news was slowly released, it didn't hit reuters until 7:07 et.



http://today.reuters.com/stocks/QuoteCompanyNewsArticle.aspx?view=CN&symbol=GNBT.O&storyid=11387+29-Nov-2005+RTRS

I just tried to buy some and it won't go thru....

Watch this one today.......
May be ready to rumble !!!! 

I am ready for this one to ''rumble'' . I'm holding 48900 shares @ .82. What makes you think GNBT could be in play today?

1/4/2006 9:00:08 AM

TORONTO, Jan 04, 2006 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT), a leader in the area of buccal drug delivery, announced today the results of a clinical trial designed to compare pharmacokinetic profiles of metformin administered by both the traditional manner (tablets) and by an alternative presentation (the Generex Metformin Gum product) that can be chewed thereby delivering metformin into the human body by way of the buccal cavity (i.e., the mouth). Generex Metformin Gum is designed as a companion product to Oral-lyn(TM), the Company's proprietary oral insulin spray product.


Metformin is used for the treatment of Type-2 diabetes mellitus in adults and children, particularly when incidental obesity and insulin resistance are present. Metformin is also used to prevent the development of diabetes in people at risk, to treat polycystic ovary syndrome (PCOS), and non-alcoholic steatohepatitis (liver disease). Metformin was approved by the FDA in December, 1994.

Diabetes results when there is a reduced production of insulin or when there is state of resistance to its action. Insulin is the hormone produced by the pancreas that lowers blood glucose levels by reducing the amount of glucose made by the liver and increasing glucose removal from the blood. Metformin increases the sensitivity of liver, muscle, fat, and other tissues to the uptake and effects of insulin, thereby lowering blood glucose levels. Unlike the sulfonylurea class glucose-lowering drugs (i.e. glyburide), metformin (a) does not increase the concentration of insulin in the blood and therefore does not cause hypoglycemia (i.e. excessively low blood glucose levels), and (b) does not cause weight gain. In fact, the weight loss observed with metformin use suggests, among others, an anoretic mechanism and a decrease in caloric expenditure. Scientific studies have indicated that metformin reduces complications associated with diabetes; nonetheless, in spite of its beneficial actions, a large number of metformin users (approximately 30%) develop significant adverse gastrointestinal (GI) effects, including diarrhea and nausea/vomiting.

The Generex study involved 10 healthy volunteers, six men with a mean age of 30 years and a mean Body Mass Index (BMI) of 23.9 and four women with a mean age of 29.8 years and a mean BMI of 21.49. The study utilized metformin tablets (Glucophage 850 mg per tablet) and Generex Metformin Gum pieces (214.5 mg per piece). Plasma metformin concentrations were sequentially measured (a) over a 12-hour period after administration of an 850 mg metformin tablet, (b) over a 24-hour period after administration of 429 mg Generex Metformin Gum (two pieces) and, (c) over a 24-hour period after administration of a 429 mg metformin tablet (a weighed fraction of the larger tablet). Plasma metformin concentrations were determined using High Performance Liquid Chromatography (HPLC) (chromatographic time was six minutes), with removal of proteins and lipids from the biological matrix by common methods prior to HPLC.

Retention time for metformin and internal standard atenolol (100 mg tablet) were 3.4 minutes and 2.9 minutes respectively. Frozen (-70 degrees) experimental specimens were unthawed for 60 minutes prior to the assay. Partial results are shown in the following graph:

The conclusion of the study is that the Generex Metformin Gum displays a pharmacokinetic profile similar to that of the metformin tablets and therefore shows promise as an alternative method of delivering metformin. The Generex Metformin Gum presentation should avoid the significant adverse gastrointestinal side-effects often accompanying the use of metformin tablets thereby improving patient compliance. In addition, Generex Metformin Gum is expected to be an ideal companion product for the Company's oral insulin, Oral-lyn. Oral-lyn is designed to offer a safe, simple, fast, effective, flexible, and familiar alternative to subcutaneous injections of prandial insulin.